Oncology

Latest News

Top 5 Most-Read Oncology Content of 2024

December 25th 2024

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Most Popular Articles of 2024 in Evidence-Based Oncology

By Mary Caffrey

December 23rd 2024

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

August 3rd 2015

Dr Jennifer Malin Predicts Biosimilars Will Have Little Impact on Treatment Costs

The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.

July 31st 2015

A Potential Tool to Predict Recurrence of HPV-Related Oropharyngeal Carcinoma

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.

July 30th 2015

New Study Claims Improved Gene Expression-Based Risk Stratification for Prostate Cancer

Surabhi Dangi-Garimella, PhD

Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.

July 29th 2015

Anti-Inflammatory Agents Improve Outcomes and QOL in Cancer Patients

Surabhi Dangi-Garimella, PhD

New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.

July 28th 2015

New Study Could Improve Precision With Pituitary Tumor Excision

Surabhi Dangi-Garimella, PhD

Physicians at the Brigham and Women's Hospital have published results from a proof-of-concept study that used mass spectrometry in almost real-time to detect and delineate pituitary tumors from normal tissue.

July 28th 2015

Two Generics Reduce Breast Cancer Deaths, Studies Find

Laura Joszt, MA

Two inexpensive generic drugs have been shown to reduce breast cancer deaths in postmenopausal women, according to studies published in The Lancet.

July 28th 2015

Electronic Data Share to Improve Cancer Outcomes

Surabhi Dangi-Garimella, PhD

The California Department of Public Health has announced participation in a pilot project with St. Joseph Health to better understand cancer trends in California.

July 27th 2015

Patient-Centered Oncology Care 2015: When Precision Medicine Meets Regulation

Before "value" became a cancer care buzzword, The American Journal of Managed Care was the first to create a conference where stakeholders discussed how to deliver the best care possible-and figure out how to pay for it. The fourth installment of Patient-Centered Oncology Care on November 19-20, 2015, in Baltimore, Maryland, will address the regulation of molecular diagnostics and ongoing efforts at payment reform.

July 25th 2015

This Week in Managed Care: July 25, 2015

This week Bristol-Myers Squibb's phase 3 nivolumab study ended early because renal cell carcinoma patients were experiencing significantly better overall survival, the American Society of Clinical Oncology called for the inclusion of more geriatric patients in trials, and Medicaid expansion states are finding more people enrolling than they planned.

July 24th 2015

Palliative Chemotherapy Can Worsen Quality of Life in End-Stage Cancer Patients

Cate Douglass

End-stage cancer patients who were in general the healthiest and most active displayed worse quality of life signs in their last week of life when they were given palliative chemotherapy and there were no benefits to overall survival.

July 24th 2015

Computational Approach Relates Gene Signatures With Cancer Outcomes

AJMC Staff

A study published in Nature Medicine has identified a gene signature that can predict cancer patient outcomes across a wide spectrum of malignancies.

July 24th 2015

Will Drug Costs Be the Big Political Issue of 2016?

Mary K. Caffrey

Recent surveys have found that public sentiment on drug costs runs high and crosses the political divide. A move this week by the nation's leading oncologists to rein in therapy pricing may be a sign that this is the breakthrough issue of the presidential campaign.

July 23rd 2015

Need for Palliative Care for Improved Performance at the End of Life

AJMC Staff

A study in JAMA Oncology has found that chemotherapy for patients with end-stage cancer was associated with worse quality of life near death while they still retained their ability to perform many life functions.

July 23rd 2015

JCO Study Concludes Improved Care and Treatment Options Responsible for Breast Cancer Survival

Surabhi Dangi-Garimella, PhD

While the study found differences in hazard ratio for age-specific survival, improved care and better treatment options might have resulted in increased survival, the authors deduce.

July 22nd 2015

Advances in Precision Medicine, Discussions on "Value" Highlight Special Issue on 2015 ASCO Meeting

A special issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care, covers clinical sessions, updates on new trial designs, and coverage of the discussion of "value" in cancer care from the 2015 meeting of the American Society of Clinical Oncology. The meeting took place May 29 to June 2, 2015, at Chicago's McCormick Convention Center.

July 22nd 2015

ASCO Releases Clinical Practical Guidelines for Decisions on Systemic Therapy for Metastatic Breast Cancer

Surabhi Dangi-Garimella, PhD

ASCO's Breast Cancer Guideline Advisory Group and Clinical Practice Guideline Committee have published an updated guideline in the Journal of Clinical Oncology on using breast cancer biomarkers to guide clinical decisions when treating advanced metastatic breast cancer.

July 22nd 2015

AJMC Staff

Zarxio (filgrastim-sndz), manufactured by Sandoz as a biosimilar to Amgen's Neupogen, has finally received marketing approval from a federal appeals court.

July 22nd 2015

Following Nivolumab, Pembrolizumab Receives EU Approval as First-Line for Melanoma

Surabhi Dangi-Garimella, PhD

Merck (MSD) has announced that its PD-1 inhibitor pembrolizumab (Keytruda) was approved by the European Commission for the treatment of advanced (unresectable or metastatic) melanoma in adults.

July 21st 2015

SGLT2 Inhibitors Can Reduce Tumor Growth

Surabhi Dangi-Garimella, PhD

Researchers at UCLA have discovered that inhibiting SGLT2 in pancreatic and prostate adenocarcinomas can reduce cancer cell survival.

July 20th 2015

ASCO Calls for Developing Oncology Trials for Geriatric Patients

AJMC Staff

The American Society of Clinical Oncology has issued a position statement in the Journal of Clinical Oncology, calling for federal agencies and the cancer research community to broaden clinical trials to include older adults.

July 20th 2015

CMS Testing Concurrent Coverage of Palliative, Curative Care

AJMC Staff

Instead of making patients suffering from life-limiting illnesses choose between hospice care and curative care, CMS will test coverage that allows individuals to receive palliative and curative treatment concurrently.

July 20th 2015

Researchers Use Precision Medicine in Common Type of Lymphoma

Laura Joszt, MA

In the first clinical study to demonstrate the importance of precision medicine in lymphomas, researchers determined that patients with a specific molecular subtype of diffuse large B-cell lymphoma responded better to ibrutinib than patients with a different molecular subtype.

July 20th 2015

Phase 3 Checkmate-025, Evaluating Nivolumab in RCC, Stopped Early

AJMC Staff

Nivolumab proved superior to everolimus in improving overall survival in previously treated patients.

July 19th 2015

Cancer Gene May Be Linked to Obesity

Laura Joszt, MA

A gene known to cause cancer may also play a role in determining obesity, according to researchers at the Virginia Commonwealth University Massey Cancer Center.

July 17th 2015

Patient Advocates Demand Oral Parity in North Carolina

AJMC Staff

The demand for oral parity for oncology medications is back up for vote in the Senate in North Carolina.

July 16th 2015

Elotuzumab Combo Delays Myeloma Progression in Phase 3 Trial

Jason M. Broderick

A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.

July 16th 2015

Annual Report on the Status of Cancer in the United States Released

AJMC Staff

The Annual Report to the Nation on Status of Cancer, product of a collaboration between The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries, has been published.

July 16th 2015

Choosing Wisely? Increased Radiation Does Not Improve Survival Outcomes in Low-Risk Prostate Cancer

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology questions aggressive local treatment strategies in men with low-risk prostate cancer.

July 16th 2015

Choosing the Ideal Lymphoma Regimens

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some new lymphoma treatments as they described their personal experience with using them during the session, "Incorporating Novel Agents Into Lymphoma Therapy: Value in Everyday Practice."

July 16th 2015

Novel Options in Melanoma and Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Immuno-oncology continues to deliver results in oncology, as seen from results presented at the annual meeting of the American Society of Clinical Oncology. The combination of nivolumab and ipilimumab significantly improved survival in melanoma, while elotozumab showed encouraging results in relapsed refractory multiple myeloma.

...

120 121 122 123 124 125 126 127 128

...

181 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions